Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + Corticosteroid

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Apr 20, 2021 → Nov 20, 2022

About Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + Corticosteroid

Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + Corticosteroid is a phase 3 stage product being developed by Gilead Sciences for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04843761. Target conditions include Covid19.

What happened to similar drugs?

4 of 15 similar drugs in Covid19 were approved

Approved (4) Terminated (5) Active (8)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04843761Phase 3Completed

Competing Products

20 competing products in Covid19

See all competitors